She will be based in Brisbane and replaces Maja McGuire in the roles.
The new executive brings to the role circa 20 years of relevant experience, gained in South Africa and Australia.
This has included working with listed companies as a general counsel, company secretary and in top-tier private practice.
Admedus, a medical technologies company, increased 10% mid-afternoon to $0.275.
Mangold has postgraduate taxation qualifications, was admitted as a solicitor in Australia in 2008, and is a member of the Queensland Law Society and Australian Institute of Company Directors.
Admedus delivers solutions that help healthcare professionals create life-changing outcomes for patients.
Next generation technologies
The company’s focus is on investing in and developing next-generation technologies with world-class partners as well as acquiring strategic assets to grow product and service offerings.
It also aims to expand revenues from its existing medical sales and distribution business. Admedus has assets from research and development through clinical development as well as sales, marketing and distribution.
The company recently introduced its ADAPT® engineered tissue technology to India, a country with circa 50 million cardiac patients and 280,000 babies born annually with a Congenital Heart Defect.
Physicians in India now have access to the benefits of the disruptive ADAPT technology and Admedus’ flagship product CardioCel® to provide life-changing outcomes for patients.